HPB P43 Stereotactic ablative radiotherapy is a safe and feasible option for non-surgical candidates with colorectal liver metastases

Abstract Background Stereotactic ablative radiotherapy (SABR) has been associated with an improvement in over-all survival patients oligometastatic colorectal cancer a controlled primary tumour and one to five lesions. We report our centre's experience of SABR as alternative local therapy for non-surgical candidates liver metastases. Methods All were identified who received irradiation metastases tertiary HPB centre between June 2016 February 2022. criteria included 1–3 metastasis maximum diameter < 6 cm, confined disease suitable performance status pre-treatment Child-Pugh A. A retrospective review the patient's scans, letters MDT outcomes was performed analyse pathology, indications outcomes. Results 18 over study period. Five female 13 male. Median age 71. Performance 1 majority cases (10/18). Only 2 had synchronous disease. 4 concomitant metastatic lung all resection. Half previous resection these having two resections 3 resections. 4/18 underwent because they deemed unfit surgery, 6/18 anatomical risk R1 down patient choice. Metastases median size 30 mm (9–87 mm). 89% (16/18) single metastasis, Overall 19 months (4–60 months). achieved complete resolution partial resolution. have stable progression. Outcome data not available patient. 2/18 pa Conclusions observed that is feasible, well tolerated effective this cohort patients. Longer-term follow up required assess benefit.